Oxycodone Hydrochloride

Vancouver, British Columbia--(News - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (" PreveCeutical " or the " Company "), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation. In his new role, he will contribute to shaping the Company's clinical development strategy and advancing key initiatives, including its Sol-gel program, Nature Identical™ peptide platform, non-addictive pain management therapies, and dopamine-based treatments targeting Parkinson's disease. Bringing extensive experience in clinical trial design, regulatory strategy, and organizational leadership, Dr. Pruthi has worked closely with global regulatory agencies such as the FDA and EMA and has been actively involved in capital markets initiatives. He currently serves as Chief Medical Officer of Relmada Therapeutics, Inc., a position he has held since June 2025. There, he leads development of the NDV-011 bladder cancer program, including a Phase 2 study and preparations for a global Phase 3 registrational trial expected to commence in early 2026. His responsibilities have included stakeholder engagement, trial execution, and collaboration with investors and regulatory authorities. He also played a central role in financing efforts that generated over $100 million through a public offering and an additional $160 million via a PIPE transaction. From 2022 to 2024, he held senior leadership roles in oncology at Johnson & Johnson Innovative Medicine (Janssen), where he contributed to late-stage clinical development, including multiple Phase 3 trials and regulatory submissions. His work supported approvals from both the FDA and EMA, including the approval of TAR-200 in 2025 for certain bladder cancer patients. He also incorporated patient-reported outcomes and digital health tools into clinical study designs. Before transitioning to industry, Dr. Pruthi spent over two decades in academia, serving as a tenured professor and Chair of Urology at leading institutions such as the University of California, San Francisco and the University of North Carolina. He is recognized for pioneering robotic surgical techniques and has shared his expertise internationally. His academic record includes more than 220 peer-reviewed publications, numerous book chapters, and hundreds of scientific presentations, along with leadership roles in national clinical guideline development. Dr. Pruthi received his medical degree from Duke University, completed his surgical and urology training at Stanford University, and earned a Master of Health Administration from the University of North Carolina at Chapel Hill. He is board-certified in urology and a Fellow of the American College of Surgeons. "I am excited to join PreveCeutical at an important stage of its evolution," said Dr. Pruthi. "The Company's commitment to developing innovative therapies based on natural and nature-identical compounds aligns closely with my professional interests. I look forward to working with the team to advance its clinical programs and address significant unmet medical needs." Stephen Van Deventer, Chairman and CEO of PreveCeutical, added: "We are very pleased to welcome Dr. Pruthi to our Board. His extensive experience in clinical development, regulatory strategy, and leadership will be invaluable as we continue to advance our pipeline. His expertise strengthens our ability to deliver innovative therapies and achieve meaningful progress across our programs." About PreveCeutical Medical Inc. PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On Behalf of the Board of Directors, PreveCeutical Medical Inc. " Stephen Van Deventer" Chairman & Chief Executive Officer For further information, please contact: Stephen Van Deventer (604) 306-9669 info@PreveCeutical.com Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at . Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. To view the source version of this press release, please visit

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate pain In both ALLEVIATE trials cebranopadol demonstrates significant and sustained pain reduction with a differentiated safety pro abdominoplasty and bunionectomy Human abuse-potential studies showing cebranopadol is l ess abusable than oxycodone and tramadol, further support its potential to offer strong pain relief with an improved safety profile MONMOUTH JUNCTION, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced debut data from its Phase 3 ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of cebranopadol, an investigational therapy, for the treatment of moderate-to-severe acute pain in patients following abdominoplasty and bunionectomy surgery, respectively, at the American Academy of Pain Medicine (AAPM) 2026 PainConnect annual meeting. The debut abstract titled, “Results of ALLEVIATE-1 and ALLEVIATE-2 Phase 3 Trials of Cebranopadol, a First-in-Class, Dual NOP/MOP Receptor Agonist for the Treatment of Acute Pain After Abdominoplasty and Bunionectomy,” was presented by Dr. Todd Bertoch, MD, Chief Medical Officer of CenExel Clinical Research, and Principal Investigator on ALLEVIATE-2. “As pain specialists, we often see how inadequately controlled acute pain can linger long after surgery or injury,” said Dr. Todd Bertoch. “If we don’t get ahead of severe pain early, it can become chronic and much harder to treat. These Phase 3 results underscore the potential of cebranopadol to redefine the standard of care for acute pain management.” Cebranopadol is an investigational, first-in-class dual nociceptin/orphanin FQ peptide (NOP) and μ-opioid peptide (MOP) receptor agonist (dual-NMR agonist). By simultaneously activating both receptors, cebranopadol is designed to provide potent analgesia while potentially mitigating many of the risks traditionally associated with preferential MOP agonists. ALLEVIATE-1 clinical trial ( NCT06545097 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study. It enrolled 303 patients undergoing abdominoplasty surgery without liposuction or other collateral procedures across four U.S. sites. Eligible participants were randomized in a 1:1:1 ratio to cebranopadol 400 µg on Days 1 and 2, cebranopadol 400 µg on Day 1 and 200 µg on Day 2 or placebo all administered once daily. The first dose was administered approximately 1 hour prior to abdominoplasty and the second dose approximately 24 hours later. ALLEVIATE-2 clinical trial ( NCT06423703 ) is a Phase 3 multicenter, randomized, double-blind, placebo-and active controlled study. It enrolled 242 patients undergoing unilateral bunionectomy with first metatarsal osteotomy across ten U.S. sites. Eligible participants were randomized in a 1:1:1 ratio to a cebranopadol 400 µg, oxycodone immediate release (IR) 10 mg or placebo. Cebranopadol was administered once daily on Days 1, 2, and 3; placebo was administered at 6, 12, and 18 hours to maintain blinding. Oxycodone 10 mg and placebo were administered every 6 hours. Baseline Demographics and Allocation: In the abdominoplasty study, 303 participants were randomized to treatment at four sites in the U.S., and 292 (96.4%) completed the study. Eleven participants discontinued the study due to adverse events (AEs) (3), lost to follow-up (2), withdrawal of consent (3), and other (3). In the bunionectomy study, 242 participants were enrolled at 10 locations in the Unites States, and 236 (97.5%) completed the study. One participant was discontinued in the oxycodone group for hypersensitivity, which was considered a severe and serious AE. No other participants discontinued or experienced a severe or serious AE. Across the two trials, baseline characteristics were similar among groups. More participants in the abdominoplasty study had a history of substance abuse. Efficacy and Safety Results The primary endpoints in both trials were met, demonstrating an acceptable benefit-risk pro cebranopadol for the treatment of acute pain following abdominoplasty and bunionectomy: In ALLEVIATE-1, the average total pain score area under the curve (AUC 4-48) for patients dosed with 400 µg cebranopadol was significantly less than placebo (LS mean difference 59.2; SE 10.14; p<0.001). In ALLEVIATE-2, the average total pain score area under the curve (AUC 2-48) for patients dosed with cebranopadol was significantly less than placebo (LS mean difference 56.1; SE 13.49; p<0.001) Following abdominoplasty, a significantly greater proportion of patients receiving cebranopadol 400 µg required no opioid rescue medication compared with those receiving placebo (34.7% vs 9.9%; p<0.001). Following bunionectomy, a significantly higher proportion of patients receiving cebranopadol 400 µg required no opioid rescue medication compared with those receiving placebo (57.5% vs 28.4%; p=0.006) Cebranopadol was generally well tolerated and exhibited a favorable safety profile. Nausea was the most common AE across study groups with exception of placebo group in the bunionectomy study. Other AEs included vomiting, constipation, headache, dizziness, hypertension and pruritus. Ketan Mehta, founder and CEO at Tris Pharma added, “Acute postoperative pain remains a significant clinical challenge, and the standard of care has serious associated risks. With our first-in-class dual NOP/MOP receptor agonist, we are taking a fundamentally new approach to pain relief, one that simultaneously targets two distinct pathways of pain modulation to deliver meaningful pain relief with a reduced risk of side effects associated with preferential MOP agonists. These data validate this mechanism of action and reinforce the potential of cebranopadol to address a critical need for safe and effective treatment options.” About Acute Pain Approximately 80 million adults in the U.S. are treated for acute pain every year 1,2 . Acute pain can be caused by injury, invasive surgery, illness, major trauma and burns. It can last up to three months and typically resolves once the underlying cause is treated or healed. Moderate-to-severe acute pain can often only be effectively treated with opioid analgesics, which, while effective, are associated with risks including respiratory depression, tolerance, dependence, misuse, and overdose. However, undertreating severe pain in the immediate period after onset can increase the risk of a patient developing chronic pain 3,4 . About Cebranopadol Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as opioid use disorder (OUD). These receptors are partially homologous to each other, and they play both complementary and distinct roles to modulate pain biology pathways. Studied in over 33 clinical trials in more than 2,200 subjects, cebranopadol’s pro been well characterized in pain management studies. It has demonstrated positive clinical results in acute pain, chronic pain, and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it could become the first dual-NMR pain-relief therapy with the potential to provide efficacy equivalent to selective MOP agonists such as oxycodone with less risk of misuse or physical dependence, addiction or overdose.  Cebranopadol’s novel mechanism of action has potential in treating patients with substance use disorders (SUDs). Tris plans to continue to evaluate cebranopadol’s potential to help patients break the cycle of opioid addiction.  The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol’s potential to treat OUDs and SUDs.  About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris markets a portfolio of best-in-class ADHD products and is developing a promising pipeline of differentiated near-term drug candidates. More information is available at  and on LinkedIn  @TrisPharma .  Media Contact Jonathan Pappas  LifeSci Communication  jpappas@lifescicomms.com Company Contact Cheryl Patnick  Tris Pharma, Inc.  cpatnick@trispharma.com ________________________ Banerjee S, Argaez C. Multidisciplinary Treatment Programs for Patients with Acute or Subacute Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Canadian Agency for Drugs and Technologies in Health. 2019 May 7; PMID: 31498579 Lopez A, Menzie AM, Kenderes M, Rubin JL. A real-world database analysis of the prevalence of pain medication use in the United States. PAIN Reports. 2026 February; DOI: 10.1097/PR9.0000000000001396 McGreevy K, Bottros MM, Raja SN. Preventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy. European Journal of Pain Supplements. 2012 Nov 11; PMID: 22102847 Sinatra, R. (2010). “Causes and Consequences of Inadequate Management of Acute Pain.” Pain Medicine, 11(12), 1859–1871. doi:10.1111/j.1526-4637.2010.00983.x